Holen Sie sich die Stockscreener-App
8.30
0.85%
0.06
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Using data filters to optimize entry into Lexeo Therapeutics Inc.Treasury Yields & AI Forecasted Stock Moves - newser.com
Can Lexeo Therapeutics Inc. stock double in next 5 yearsMarket Activity Recap & Accurate Intraday Trading Signals - newser.com
Will Lexeo Therapeutics Inc. stock outperform Nasdaq indexSell Signal & Precise Swing Trade Entry Alerts - newser.com
Using flow based indicators on Lexeo Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - newser.com
Best data tools to analyze Lexeo Therapeutics Inc. stockInsider Selling & AI Enhanced Trading Alerts - newser.com
Leerink Partnrs Issues Positive Forecast for LXEO Earnings - Defense World
Lexeo Therapeutics, Inc.: A Deep Dive (NASDAQ:LXEO) - Seeking Alpha
How to monitor Lexeo Therapeutics Inc. with trend dashboardsMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Smart tools for monitoring Lexeo Therapeutics Inc.’s price action2025 Pullback Review & Daily Stock Trend Reports - newser.com
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease - streetwisereports.com
Analyzing recovery setups for Lexeo Therapeutics Inc. investorsJobs Report & Verified Chart Pattern Signals - newser.com
Biotech Firm Uncovers Breakthrough Gene Therapy in New York - streetwisereports.com
How to integrate Lexeo Therapeutics Inc. into portfolio analysis toolsJuly 2025 Price Swings & High Conviction Trade Alerts - newser.com
Is a relief rally coming for Lexeo Therapeutics Inc. holdersWeekly Profit Summary & Free Weekly Watchlist of Top Performers - newser.com
Lexeo Therapeutics Announces Progress in FDA Discussions and Positive Interim Data for LX2006 - TradingView
Is Lexeo Therapeutics Inc. a candidate for recovery playBond Market & Free Community Consensus Stock Picks - newser.com
Why Lexeo Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Reactions & Community Supported Trade Ideas - newser.com
Therapeutics Company Advances Gene Therapy Breakthrough - streetwisereports.com
Lexeo Therapeutics reports on LX2006 approval pathway - MSN
Chardan Raises Price Target on Lexeo Therapeutics to $17 From $15, Keeps Buy Rating - MarketScreener
HC Wainwright & Co. Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Leerink Partners Issues Positive Forecast for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In - Stocktwits
Chardan Capital Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO) - Seeking Alpha
Lexeo, FDA position Friedreich ataxia therapy for accelerated path - BioWorld MedTech
Positive Outlook for Lexeo Therapeutics: Regulatory Advancements and Promising LX2006 Data Boost Stock Target - TipRanks
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - Stocktwits
Lexeo says FDA open to speedier approval of rare disease gene therapy - BioPharma Dive
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment - MarketScreener
Lexeo up after regulatory update on ataxia drug (LXEO:NASDAQ) - Seeking Alpha
Lexeo’s gene therapy for Friedreich ataxia shows promising results By Investing.com - Investing.com Canada
Lexeo Therapeutics Advances FDA Discussions for LX2006 - TipRanks
Lexeo Therapeutics announces progress in FDA discussions for LX006 in Friedreich ataxia cardiomyopathy - MarketScreener
Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway for LX2006 in Friedreich Ataxia with Promising Interim Data - Quiver Quantitative
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - The Manila Times
Lexeo Therapeutics Announces Progress In FDA Discussions For LX006 In Friedreich Ataxia Cardiomyopathy - TradingView
23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling - Stock Titan
Can a trend reversal in Lexeo Therapeutics Inc. lead to recoveryJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Is Lexeo Therapeutics Inc. stock a top momentum playRate Hike & Daily Growth Stock Investment Tips - newser.com
Can Lexeo Therapeutics Inc. recover in the next quarterDip Buying & Verified Swing Trading Watchlist - newser.com
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):